|
|
|
|
|
|
News and Articles on Oncolytics Biotech (ONCY)
Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results Jul 30, 2009
CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:) ("Oncolytics" or the "Company") today announced its financial results for the three and six-month periods ended June 30, 2009 ... 9 million; - In early July, completed patient enrolment in the Phase II component of our U.K. REOLYSIN and paclitaxel/carboplatin clinical trial; and, - In mid-July, announced that we had completed the lyophilization (freeze-drying) formulation development program for REOLYSIN.... (PR Newswire)
Common Virus Kills Cancer Stem Cells Apr 10, 2009
A Calgary-based company, Oncolytics Biotech Inc., is testing reovirus in clinical trials to prove the treatments are safe and effective. Unlike most cancer studies, which use cancer cell lines developed for laboratory use, this study used fresh breast cancer tissue. (Science Daily)
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 Mar 5, 2009
CALGARY, March 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2008 ... "We look forward to taking REOLYSIN into to the final stages of development in 2009." Oncolytics Biotech Inc. CONSOLIDATED BALANCE SHEETS As at December 31 2008 2007 $ $ ------------------------------------------------------------------------- ASSETS Current Cash and cash equivalents 7,429,895 6,715,096... (PR Newswire)
[ Terms Of Use | Privacy | About ]
©1998-2006 SurfWax, Inc.
All rights reserved. Patents pending.
|
|
|
Copyright SurfWax, Inc. 2006
|
|
